DOCSLIB.ORG

Systemic Lupus Erythematosus: Pathogenesis 20 and Clinical Features

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Systemic Lupus Erythematosus: Pathogenesis 20 and Clinical Features Systemic Lupus Erythematosus: Pathogenesis 20 and Clinical Features George Bertsias, Ricard Cervera, Dimitrios T Boumpas A previous version was coauthored by Ricard Cervera, Gerard Espinosa and David D’Cruz Learning objectives: • Use the epidemiology and natural history of nervous, gastrointestinal, and haematological systemic lupus erythematosus (SLE) to inform systems diagnostic and therapeutic decisions • Evaluate the challenges in the diagnosis and • Describe and explain the key events in the differential diagnosis of lupus and the pitfalls pathogenesis of SLE and critically analyse the in the tests used to diagnose and monitor contribution of genetics, epigenetics, hormonal, lupus activity and environmental factors to the immune • Identify important aspects of the disease such aberrancies found in the disease as women’s health issues (ie, contraception and • Explain the key symptoms and signs of the pregnancy) and critical illness diseases and the tissue damage associated • Outline the patterns of SLE expression in with SLE specific subsets of patients depending on age, • State the classification criteria of lupus and their gender, ethnicity, and social class limitations when used for diagnostic purposes • Classify and assess patients according to • Describe and explain the clinical manifestations the severity of system involvement and use of SLE in the musculoskeletal, dermatological, appropriate clinical criteria to stratify patients in renal, respiratory, cardiovascular, central terms of the risk of morbidity and mortality 1 Introduction ‘wolf’s bite’. In 1846 the Viennese physician Ferdinand von Hebra (1816–1880) introduced the butterfl y metaphor to Systemic lupus erythematosus (SLE) is the prototypic describe the malar rash. He also used the term ‘lupus multisystem autoimmune disorder with a broad spectrum erythematosus’ and published the fi rst illustrations in his of clinical presentations encompassing almost all organs Atlas of Skin Diseases in 1856. Lupus was fi rst recognised as a and tissues. Th e extreme heterogeneity of the disease has systemic disease with visceral manifestations by Moriz Kaposi led some investigators to propose that SLE represents a (1837–1902). Th e systemic form was further established by syndrome rather than a single disease. Osler in Baltimore and Jadassohn in Vienna. Other important milestones include the description of the false positive test for 2 Major milestones in the history of syphilis in SLE by Reinhart and Hauck from Germany (1909); lupus the description of the endocarditis lesions in SLE by Libman Th e term ‘lupus’ (Latin for ‘wolf’) was fi rst used during the and Sacks in New York (1923); the description of the Middle Ages to describe erosive skin lesions evocative of a glomerular changes by Baehr (1935), and the use of the term 476 220_Eular_Fpp.indd0_Eular_Fpp.indd 447676 44/21/2012/21/2012 77:37:54:37:54 PPMM Systemic Lupus Erythematosus: Pathogenesis and Clinical Features ‘diff use connective tissue disease’ by Klemperer, Pollack and disease starts with a preclinical phase characterised by Baehr (1941). Th e beginning of the modern era in SLE was autoantibodies common to other systemic autoimmune the discovery of the ‘LE’ cell by Hargraves, Richmond and diseases and proceeds with a more disease-specifi c Morton at the Mayo Clinic in 1948. clinically overt autoimmune phase (Bertsias et al 2010a). During its course periods of fl ares intercept periods of remission culminating in disease- and therapy-related 3 Epidemiology damage, such as alopecia, fi xed erythema, cognitive Prevalence rates in lupus are estimated to be as high as 51 per dysfunction, valvular heart disease, avascular necrosis, 100 000 people in the USA. Th e incidence of lupus has nearly tendon rupture, Jaccoud’s arthropathy, and osteoporosis. tripled in the last 40 years, mainly due to improved diagnosis Early damage is mostly related to disease whereas late of mild disease. Estimated incidence rates in North America, damage—namely infections, atherosclerosis, and South America, and Europe range from 2 to 8 per 100 000 malignancies—is usually related to complications of per year. Women are aff ected nine times more frequently longstanding disease and immunosuppressive therapy. than men and African American and Latin American mestizos are aff ected much more frequently than Caucasians, and have higher disease morbidity. Th e disease appears to be 5 Aetiology and pathogenesis more common in urban than rural areas. Sixty-fi ve per cent Th e aetiology of SLE includes both genetic and of patients with SLE have disease onset between the ages of environmental components with female sex strongly 16 and 55 years, 20% present before age 16, and 15% aft er the infl uencing pathogenesis. Th ese factors lead to an age of 55. Men with lupus tend to have less photosensitivity, irreversible break in immunological tolerance manifested by more serositis, an older age at diagnosis, and a higher 1 year immune responses against endogenous nuclear antigens. mortality compared to women. SLE tends to be milder in the elderly with lower incidence of malar rash, photosensitivity, purpura, alopecia, Raynaud’s phenomenon, renal and central 5.1 Genetic factors nervous system involvement, but greater prevalence of Siblings of SLE patients are approximately 30 times more serositis, pulmonary involvement, sicca symptoms, and likely to develop SLE compared with individuals without musculoskeletal manifestations. an aff ected sibling. Th e rate of gene discovery in SLE has increased during the past few years thanks to large genome-wide association studies (GWAS) using hundreds 4 Natural history and course of thousands of single nucleotide polymorphism (SNP) SLE is a chronic disease of variable severity with a waxing markers (fi gure 2). and waning course, with signifi cant morbidity that can be GWAS in lupus have confi rmed the importance of genes fatal—if not treated early—in some patients (fi gure 1). Th e associated with immune response and infl ammation Figure 1 Natural history of systemic lupus erythematosus. SLICC, Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index. Reprinted with permission from Bertsias GK, Salmon JE, Boumpas DT. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann Rheum Dis 2010;69:1603–11. 477 220_Eular_Fpp.indd0_Eular_Fpp.indd 447777 44/21/2012/21/2012 77:37:55:37:55 PPMM EULAR Textbook on Rheumatic Diseases Figure 2 Manhattan plot of a genome-wide association study (GWAS) in systemic lupus erythematosus (SLE) involving 1311 cases and 3340 controls of European ancestry. Each dot in this fi gure (known as a Manhattan plot) corresponds to a genetic marker that, in this particular study, included ~550 000 single nucleotide polymorphisms (SNPs). Dots are colour coded and arranged along the x-axis according to position with each colour representing a different chromosome. The y-axis represents the signifi cance level (–log P value) for the association of each SNP with SLE (ie, comparison between SLE cases and controls). Because of the multiple testing the level of signifi cance for defi nitive genetic associations is quite high in the range of approximately 5×10–8 while results between –log P values of approximately 5–7 are considered as associations of borderline signifi cance. Reprinted with permission from Criswell LA. Genome-wide association studies of SLE. What do these studies tell us about disease mechanisms in lupus? The Rheumatologist 2011. (HLA-DR, PTPN22, STAT4, IRF5, BLK, OX40L, FCGR2A, 5.3 Environmental factors BANK1, SPP1, IRAK1, TNFAIP3, C2, C4, CIq, PXK), DNA Candidate environmental triggers of SLE include ultraviolet repairs (TREX1), adherence of infl ammatory cells to the light, demethylating drugs, and infectious or endogenous endothelium (ITGAM), and tissue response to injury (KLK1, viruses or viral-like elements. Sunlight is the most obvious KLK3). Th ese fi ndings highlight the importance of Toll-like environmental factor that may exacerbate SLE. Epstein– receptor (TLR) and type 1 interferon (IFN) signalling Barr virus (EBV) has been identifi ed as a possible factor in pathways. Some of the genetic loci may explain not only the the development of lupus. EBV may reside in and interact susceptibility to disease but also its severity. For instance, with B cells and promotes interferon α (IFNα) production STAT4, a genetic risk factor for rheumatoid arthritis and SLE, by plasmacytoid dendritic cells (pDCs), suggesting that is associated with severe SLE. One of the key components of elevated IFNα in lupus may be—at least in part—due to these pathways is TNFAIP3, which has been implicated in at aberrantly controlled chronic viral infection. least six autoimmune disorders, including SLE. It is well established that certain drugs induce autoantibodies in a signifi cant number of patients, most of 5.2 Epigenetic effects whom do not develop signs of an autoantibody associated disease. Over 100 drugs have been reported to cause Th e risk for SLE may be infl uenced by epigenetic eff ects drug-induced lupus (DIL), including a number of the newer such as DNA methylation and post-translational biologics and antiviral agents. Although the pathogenesis of modifi cations of histones, which can be either inherited or DIL is not well understood, a genetic predisposition may environmentally modifi ed. Epigenetics refers to inherited play a role in the case of certain drugs, particularly those changes in gene expression caused by mechanisms other agents that are metabolised by acetylation such as than DNA base sequence changes. Th e most well procainamide and hydralazine, with disease more likely to understood type of epigenetic factor is DNA methylation, develop in patients who are slow acetylators. Th ese drugs which plays a role in a variety of human processes, such as may alter gene expression in CD4+ T cells by inhibiting X chromosome inactivation and certain cancers. Previous DNA methylation and induce over-expression of LFA-1 research has also implicated the importance of DNA antigen, thus promoting autoreactivity.
Load more

Recommended publications
  • 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis
    ARTHRITIS & RHEUMATISM Vol. 65, No. 10, October 2013, pp 2499–2512 DOI 10.1002/art.38092 © 2013, American College of Rheumatology Arthritis & Rheumatism An Official Journal of the American College of Rheumatology www.arthritisrheum.org and wileyonlinelibrary.com SPECIAL ARTICLE 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications Sarah Ringold,1 Pamela F. Weiss,2 Timothy Beukelman,3 Esi Morgan DeWitt,4 Norman T. Ilowite,5 Yukiko Kimura,6 Ronald M. Laxer,7 Daniel J. Lovell,4 Peter A. Nigrovic,8 Angela Byun Robinson,9 and Richard K. Vehe10 Guidelines and recommendations developed and/or endorsed by the American College of Rheumatology (ACR) are intended to provide guidance for particular patterns of practice and not to dictate the care of a particular patient. The ACR considers adherence to these guidelines and recommendations to be voluntary, with the ultimate determina- tion regarding their application to be made by the physician in light of each patient’s individual circumstances. Guidelines and recommendations are intended to promote beneficial or desirable outcomes but cannot guarantee any specific outcome. Guidelines and recommendations developed or endorsed by the ACR are subject to periodic revi- sion as warranted by the evolution of medical knowledge, technology, and practice. The American College of Rheumatology is an independent, professional, medical and scientific society which does not guarantee, warrant, or endorse any commercial product or service. INTRODUCTION tions represented the first such effort by the ACR that focused entirely on the treatment of a pediatric rheu- The American College of Rheumatology (ACR) matic disease, and included recommendations for the published treatment recommendations for juvenile idio- initial and subsequent treatment of patients with syno- pathic arthritis (JIA) in 2011 (1).
    [Show full text]
  • Role of NS1 Antibodies in the Pathogenesis of Acute Secondary Dengue Infection
    ARTICLE DOI: 10.1038/s41467-018-07667-z OPEN Role of NS1 antibodies in the pathogenesis of acute secondary dengue infection Deshni Jayathilaka1, Laksiri Gomes1, Chandima Jeewandara1, Geethal.S.Bandara Jayarathna1, Dhanushka Herath1, Pathum Asela Perera1, Samitha Fernando1, Ananda Wijewickrama2, Clare S. Hardman3, Graham S. Ogg3 & Gathsaurie Neelika Malavige 1,3 The role of NS1-specific antibodies in the pathogenesis of dengue virus infection is poorly 1234567890():,; understood. Here we investigate the immunoglobulin responses of patients with dengue fever (DF) and dengue hemorrhagic fever (DHF) to NS1. Antibody responses to recombinant-NS1 are assessed in serum samples throughout illness of patients with acute secondary DENV1 and DENV2 infection by ELISA. NS1 antibody titres are significantly higher in patients with DHF compared to those with DF for both serotypes, during the critical phase of illness. Furthermore, during both acute secondary DENV1 and DENV2 infection, the antibody repertoire of DF and DHF patients is directed towards distinct regions of the NS1 protein. In addition, healthy individuals, with past non-severe dengue infection have a similar antibody repertoire as those with mild acute infection (DF). Therefore, antibodies that target specific NS1 epitopes could predict disease severity and be of potential benefit in aiding vaccine and treatment design. 1 Centre for Dengue Research, University of Sri Jayewardenepura, Nugegoda 10100, Sri Lanka. 2 National Institute of Infectious Diseases, Angoda 10250, Sri Lanka. 3 MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Oxford NIHR Biomedical Research Centre, Oxford OX3 9DS, UK. These authors contributed equally: Deshni Jayathilaka, Laksiri Gomes. The authors jointly supervised this work: Graham S.
    [Show full text]
  • Dermatologic Manifestations and Complications of COVID-19
    American Journal of Emergency Medicine 38 (2020) 1715–1721 Contents lists available at ScienceDirect American Journal of Emergency Medicine journal homepage: www.elsevier.com/locate/ajem Dermatologic manifestations and complications of COVID-19 Michael Gottlieb, MD a,⁎,BritLong,MDb a Department of Emergency Medicine, Rush University Medical Center, United States of America b Department of Emergency Medicine, Brooke Army Medical Center, United States of America article info abstract Article history: The novel coronavirus disease of 2019 (COVID-19) is associated with significant morbidity and mortality. While Received 9 May 2020 much of the focus has been on the cardiac and pulmonary complications, there are several important dermato- Accepted 3 June 2020 logic components that clinicians must be aware of. Available online xxxx Objective: This brief report summarizes the dermatologic manifestations and complications associated with COVID-19 with an emphasis on Emergency Medicine clinicians. Keywords: COVID-19 Discussion: Dermatologic manifestations of COVID-19 are increasingly recognized within the literature. The pri- fi SARS-CoV-2 mary etiologies include vasculitis versus direct viral involvement. There are several types of skin ndings de- Coronavirus scribed in association with COVID-19. These include maculopapular rashes, urticaria, vesicles, petechiae, Dermatology purpura, chilblains, livedo racemosa, and distal limb ischemia. While most of these dermatologic findings are Skin self-resolving, they can help increase one's suspicion for COVID-19. Emergency medicine Conclusion: It is important to be aware of the dermatologic manifestations and complications of COVID-19. Knowledge of the components is important to help identify potential COVID-19 patients and properly treat complications. © 2020 Elsevier Inc.
    [Show full text]
  • Dermatological Findings in Common Rheumatologic Diseases in Children
    Available online at www.medicinescience.org Medicine Science ORIGINAL RESEARCH International Medical Journal Medicine Science 2019; ( ): Dermatological findings in common rheumatologic diseases in children 1Melike Kibar Ozturk ORCID:0000-0002-5757-8247 1Ilkin Zindanci ORCID:0000-0003-4354-9899 2Betul Sozeri ORCID:0000-0003-0358-6409 1Umraniye Training and Research Hospital, Department of Dermatology, Istanbul, Turkey. 2Umraniye Training and Research Hospital, Department of Child Rheumatology, Istanbul, Turkey Received 01 November 2018; Accepted 19 November 2018 Available online 21.01.2019 with doi:10.5455/medscience.2018.07.8966 Copyright © 2019 by authors and Medicine Science Publishing Inc. Abstract The aim of this study is to outline the common dermatological findings in pediatric rheumatologic diseases. A total of 45 patients, nineteen with juvenile idiopathic arthritis (JIA), eight with Familial Mediterranean Fever (FMF), six with scleroderma (SSc), seven with systemic lupus erythematosus (SLE), and five with dermatomyositis (DM) were included. Control group for JIA consisted of randomly chosen 19 healthy subjects of the same age and gender. The age, sex, duration of disease, site and type of lesions on skin, nails and scalp and systemic drug use were recorded. χ2 test was used. The most common skin findings in patients with psoriatic JIA were flexural psoriatic lesions, the most common nail findings were periungual desquamation and distal onycholysis, while the most common scalp findings were erythema and scaling. The most common skin finding in patients with oligoarthritis was photosensitivity, while the most common nail finding was periungual erythema, and the most common scalp findings were erythema and scaling. We saw urticarial rash, dermatographism, nail pitting and telogen effluvium in one patient with systemic arthritis; and photosensitivity, livedo reticularis and periungual erythema in another patient with RF-negative polyarthritis.
    [Show full text]
  • Corneal Endotheliitis with Cytomegalovirus Infection of Persisted
    Correspondence 1105 Sir, resulted in gradual decreases of KPs, but graft oedema Corneal endotheliitis with cytomegalovirus infection of persisted. Vision decreased to 20/2000. corneal stroma The patient underwent a second keratoplasty combined with cataract surgery in August 2007. Although involvement of cytomegalovirus (CMV) in The aqueous humour was tested for polymerase corneal endotheliitis was recently reported, the chain reaction to detect HSV, VZV, or CMV; a positive pathogenesis of this disease remains uncertain.1–8 Here, result being obtained only for CMV-DNA. Pathological we report a case of corneal endotheliitis with CMV examination demonstrated granular deposits in the infection in the corneal stroma. deep stroma, which was positive for CMV by immunohistochemistry (Figures 2a and b). The cells showed a typical ‘owl’s eye’ morphology (Figure 2c). Case We commenced systemic gancyclovir at 10 mg per day A 44-year-old man was referred for a gradual decrease in for 7 days, followed by topical 0.5% gancyclovir eye vision with a history of recurrent iritis with unknown drops six times a day. With the postoperative follow-up aetiology. The corrected visual acuity in his right eye was period of 20 months, the graft remained clear without 20/200. Slit lamp biomicroscopy revealed diffuse corneal KPs (Figure 1d). The patient has been treated with oedema with pigmented keratic precipitates (KPs) gancyclovir eye drops t.i.d. to date. His visual acuity without anterior chamber cellular reaction (Figure 1a). improved to 20/20, and endothelial density was The patient had undergone penetrating keratoplasty in 2300/mm2. Repeated PCR in aqueous humour for August 2006, and pathological examination showed non- CMV yielded a negative result in the 10th week.
    [Show full text]
  • Psoriasis, a Systemic Disease Beyond the Skin, As Evidenced by Psoriatic Arthritis and Many Comorbities
    1 Psoriasis, a Systemic Disease Beyond the Skin, as Evidenced by Psoriatic Arthritis and Many Comorbities – Clinical Remission with a Leishmania Amastigotes Vaccine, a Serendipity Finding J.A. O’Daly Astralis Ltd, Irvington, NJ USA 1. Introduction Psoriasis is a systemic chronic, relapsing inflammatory skin disorder, with worldwide distribution, affects 1–3% of the world population, prevalence varies according to race, geographic location, and environmental factors (Chandran & Raychaudhuri, 2010; Christophers & Mrowietz, 2003; Farber & Nall, 1974). In Germany, 33,981 from 1,344,071 continuously insured persons in 2005 were diagnosed with psoriasis; thus the one year prevalence was 2.53% in the study group. Up to the age of 80 years the prevalence rate (range: 3.99-4.18%) was increasing with increasing age and highest for the age groups from 50 to 79 years The total rate of psoriasis in children younger than 18 years was 0.71%. The prevalence rates increased in an approximately linear manner from 0.12% at the age of 1 year to 1.2% at the age of 18 years (Schäfer et al., 2011). In France, a case-control study in 6,887 persons, 356 cases were identified (5.16%), who declared having had psoriasis during the previous 12 months (Wolkenstein et al., 2009). The prevalence of psoriasis analyzed across Italy showed that 2.9% of Italians declared suffering from psoriasis (regional range: 0.8-4.5%) in a total of 4109 individuals (Saraceno et al., 2008). The overall rate of comorbidity in subjects with psoriasis aged less than 20 years was twice as high as in subjects without psoriasis.
    [Show full text]
  • Review Cutaneous Patterns Are Often the Only Clue to a a R T I C L E Complex Underlying Vascular Pathology
    pp11 - 46 ABstract Review Cutaneous patterns are often the only clue to a A R T I C L E complex underlying vascular pathology. Reticulate pattern is probably one of the most important DERMATOLOGICAL dermatological signs of venous or arterial pathology involving the cutaneous microvasculature and its MANIFESTATIONS OF VENOUS presence may be the only sign of an important underlying pathology. Vascular malformations such DISEASE. PART II: Reticulate as cutis marmorata congenita telangiectasia, benign forms of livedo reticularis, and sinister conditions eruptions such as Sneddon’s syndrome can all present with a reticulate eruption. The literature dealing with this KUROSH PARSI MBBS, MSc (Med), FACP, FACD subject is confusing and full of inaccuracies. Terms Departments of Dermatology, St. Vincent’s Hospital & such as livedo reticularis, livedo racemosa, cutis Sydney Children’s Hospital, Sydney, Australia marmorata and retiform purpura have all been used to describe the same or entirely different conditions. To our knowledge, there are no published systematic reviews of reticulate eruptions in the medical Introduction literature. he reticulate pattern is probably one of the most This article is the second in a series of papers important dermatological signs that signifies the describing the dermatological manifestations of involvement of the underlying vascular networks venous disease. Given the wide scope of phlebology T and its overlap with many other specialties, this review and the cutaneous vasculature. It is seen in benign forms was divided into multiple instalments. We dedicated of livedo reticularis and in more sinister conditions such this instalment to demystifying the reticulate as Sneddon’s syndrome. There is considerable confusion pattern.
    [Show full text]
  • Pathology and Pathogenesis of SARS-Cov-2 Associated with Fatal Coronavirus Disease, United States Roosecelis B
    Pathology and Pathogenesis of SARS-CoV-2 Associated with Fatal Coronavirus Disease, United States Roosecelis B. Martines,1 Jana M. Ritter,1 Eduard Matkovic, Joy Gary, Brigid C. Bollweg, Hannah Bullock, Cynthia S. Goldsmith, Luciana Silva-Flannery, Josilene N. Seixas, Sarah Reagan-Steiner, Timothy Uyeki, Amy Denison, Julu Bhatnagar, Wun-Ju Shieh, Sherif R. Zaki; COVID-19 Pathology Working Group2 An ongoing pandemic of coronavirus disease (CO- United States; since then, all 50 US states, District of VID-19) is caused by infection with severe acute respi- Columbia, Guam, Puerto Rico, Northern Mariana Is- ratory syndrome coronavirus 2 (SARS-CoV-2). Charac- lands, and US Virgin Islands have confirmed cases of terization of the histopathology and cellular localization COVID-19 (2–4). of SARS-CoV-2 in the tissues of patients with fatal CO- Coronaviruses are enveloped, positive-strand- VID-19 is critical to further understand its pathogenesis ed RNA viruses that infect many animals; human- and transmission and for public health prevention mea- adapted viruses likely are introduced through zoo- sures. We report clinicopathologic, immunohistochemi- notic transmission from animal reservoirs (5,6). Most cal, and electron microscopic findings in tissues from known human coronaviruses are associated with 8 fatal laboratory-confirmed cases of SARS-CoV-2 in- mild upper respiratory illness. SARS-CoV-2 belongs fection in the United States. All cases except 1 were in to the group of betacoronaviruses that includes severe residents of long-term care facilities. In these patients, SARS-CoV-2 infected epithelium of the upper and lower acute respiratory syndrome coronavirus (SARS-CoV) airways with diffuse alveolar damage as the predominant and Middle East respiratory syndrome coronavirus pulmonary pathology.
    [Show full text]
  • Celiac Disease and Nonceliac Gluten Sensitivitya Review
    Clinical Review & Education JAMA | Review Celiac Disease and Nonceliac Gluten Sensitivity A Review Maureen M. Leonard, MD, MMSc; Anna Sapone, MD, PhD; Carlo Catassi, MD, MPH; Alessio Fasano, MD CME Quiz at IMPORTANCE The prevalence of gluten-related disorders is rising, and increasing numbers of jamanetwork.com/learning individuals are empirically trying a gluten-free diet for a variety of signs and symptoms. This review aims to present current evidence regarding screening, diagnosis, and treatment for celiac disease and nonceliac gluten sensitivity. OBSERVATIONS Celiac disease is a gluten-induced immune-mediated enteropathy characterized by a specific genetic genotype (HLA-DQ2 and HLA-DQ8 genes) and autoantibodies (antitissue transglutaminase and antiendomysial). Although the inflammatory process specifically targets the intestinal mucosa, patients may present with gastrointestinal signs or symptoms, extraintestinal signs or symptoms, or both, Author Affiliations: Center for Celiac suggesting that celiac disease is a systemic disease. Nonceliac gluten sensitivity Research and Treatment, Division of is diagnosed in individuals who do not have celiac disease or wheat allergy but who Pediatric Gastroenterology and Nutrition, MassGeneral Hospital for have intestinal symptoms, extraintestinal symptoms, or both, related to ingestion Children, Boston, Massachusetts of gluten-containing grains, with symptomatic improvement on their withdrawal. The (Leonard, Sapone, Catassi, Fasano); clinical variability and the lack of validated biomarkers for nonceliac gluten sensitivity make Celiac Research Program, Harvard establishing the prevalence, reaching a diagnosis, and further study of this condition Medical School, Boston, Massachusetts (Leonard, Sapone, difficult. Nevertheless, it is possible to differentiate specific gluten-related disorders from Catassi, Fasano); Shire, Lexington, other conditions, based on currently available investigations and algorithms.
    [Show full text]
  • A Patient with Plaque Type Morphea Mimicking Systemic Lupus Erythematosus
    CASE REPORT A Patient With Plaque Type Morphea Mimicking Systemic Lupus Erythematosus Wardhana1, EA Datau2 1 Department of Internal Medicine, Siloam International Hospitals. Karawaci, Indonesia. 2 Department of Internal Medicine, Prof. Dr. RD Kandou General Hospital & Sitti Maryam Islamic Hospital, Manado, North Sulawesi, Indonesia. Correspondence mail: Siloam Hospitals Group’s CEO Office, Siloam Hospital Lippo Village. 5th floor. Jl. Siloam No.6, Karawaci, Indonesia. email: [email protected] ABSTRAK Morfea merupakan penyakit jaringan penyambung yang jarang dengan gambaran utama berupa penebalan dermis tanpa disertai keterlibatan organ dalam. Penyakit ini juga dikenal sebagai bagian dari skleroderma terlokalisir. Berdasarkan gambaran klinis dan kedalaman jaringan yang terlibat, morfea dikelompokkan ke dalam beberapa bentuk dan sekitar dua pertiga orang dewasa dengan morfea mempunyai tipe plak. Produksi kolagen yang berlebihan oleh fibroblast merupakan penyebab kelainan pada morfea dan mekanisme terjadinya aktivitas fibroblast yang berlebihan ini masih belum diketahui, meskipun beberapa mekanisme pernah diajukan. Morfe tipe plak biasanya bersifat ringan dan dapat sembuh dengan sendirinya. Morfea tipe plak yang penampilan klinisnya menyerupai lupus eritematosus sistemik, misalnya meliputi alopesia dan ulkus mukosa di mulut, jarang dijumpai. Sebuah kasus morfea tipe plak pada wanita berusia 20 tahun dibahas. Pasien ini diobati dengan imunosupresan dan antioksidan local maupun sistemik. Kondisi paisen membaik tanpa disertai efek samping yang berarti. Kata kunci: morfea, tipe plak. ABSTRACT Morphea is an uncommon connective tissue disease with the most prominent feature being thickening or fibrosis of the dermal without internal organ involvement. It is also known as a part of localized scleroderma. Based on clinical presentation and depth of tissue involvement, morphea is classified into several forms, and about two thirds of adults with morphea have plaque type.
    [Show full text]
  • Does Previous Corticosteroid Treatment Affect the Inflammatory Infiltrate Found in Polymyositis Muscle Biopsies? M.M
    Does previous corticosteroid treatment affect the inflammatory infiltrate found in polymyositis muscle biopsies? M.M. Pinhata1, J.J. Nascimento1, S.K.N. Marie2, S.K. Shinjo1 1Division of Rheumatology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil; 2Laboratory of Molecular and Cellular Biology, Department of Neurology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. Abstract Objective The aim of the study was to evaluate the effect of the prior use of corticosteroids (CS) on the presence of inflammatory infiltrates (InI) in muscle biopsies of polymyositis (PM). Methods We retrospectively evaluated 60 muscle biopsy samples that had been obtained at the time of the diagnosis of PM. The patients were divided into three groups according to the degree of the InI present in the muscle biopsies: (a) minimal InI present only in an interstitial area of the muscle biopsy (endomysium, perimysium) or in a perivascular area; (B) moderate InI in one or two areas of the interstitium or of the perivascular area; and (C) moderate InI throughout the interstitium or intense inflammation in at least one area of the interstitium or of the perivascular area. Results The three groups were comparable regarding the demographic, clinical and laboratory features (p>0.05). Approximately half of the patients in each group were using CS at the time of the muscle biopsy. The median (interquartile) duration of CS use [4 (0-38), 4 (0–60) and 5 (0–60) days: groups A, B and C, respectively] and the median cumulative CS dose used [70 (0–1200), 300 (0–1470) and 300 (0–1800)mg] were similar between the groups (p>0.05).
    [Show full text]
  • Differential Diagnosis of Juvenile Idiopathic Arthritis
    pISSN: 2093-940X, eISSN: 2233-4718 Journal of Rheumatic Diseases Vol. 24, No. 3, June, 2017 https://doi.org/10.4078/jrd.2017.24.3.131 Review Article Differential Diagnosis of Juvenile Idiopathic Arthritis Young Dae Kim1, Alan V Job2, Woojin Cho2,3 1Department of Pediatrics, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea, 2Department of Orthopaedic Surgery, Albert Einstein College of Medicine, 3Department of Orthopaedic Surgery, Montefiore Medical Center, New York, USA Juvenile idiopathic arthritis (JIA) is a broad spectrum of disease defined by the presence of arthritis of unknown etiology, lasting more than six weeks duration, and occurring in children less than 16 years of age. JIA encompasses several disease categories, each with distinct clinical manifestations, laboratory findings, genetic backgrounds, and pathogenesis. JIA is classified into sev- en subtypes by the International League of Associations for Rheumatology: systemic, oligoarticular, polyarticular with and with- out rheumatoid factor, enthesitis-related arthritis, psoriatic arthritis, and undifferentiated arthritis. Diagnosis of the precise sub- type is an important requirement for management and research. JIA is a common chronic rheumatic disease in children and is an important cause of acute and chronic disability. Arthritis or arthritis-like symptoms may be present in many other conditions. Therefore, it is important to consider differential diagnoses for JIA that include infections, other connective tissue diseases, and malignancies. Leukemia and septic arthritis are the most important diseases that can be mistaken for JIA. The aim of this review is to provide a summary of the subtypes and differential diagnoses of JIA. (J Rheum Dis 2017;24:131-137) Key Words.
    [Show full text]